Marksans Pharma Limited — Updates, 11-02-2025: Press Release

Marksans Pharma Ltd. reported sustained double-digit year-on-year growth for the third quarter and nine months ended December 31, 2024, with revenue reaching Rs. 681.8 Cr., a 16.3% increase YoY. This growth was driven primarily by the US market, which experienced a remarkable 37% growth, contributing significantly to an all-time high PAT of Rs. 105 Cr., marking a 26.6% increase from the previous year.

The overall financial performance showed gross profit of Rs. 383.5 Cr., reflecting a 22.4% YoY rise and a gross margin expansion of 279 bps to 56.2%. EBITDA grew 4.3% YoY to Rs. 138.8 Cr., with a margin of 20.4%. For the first nine months, revenue reached Rs. 1,914.4 Cr., up 18.4% YoY, while the gross profit and EBITDA rose 29.1% and 15.5%, respectively.

Looking ahead, the company plans 34 new filings in the UK and Europe over the next three years and is optimistic about ongoing growth driven by new product launches and expansion of the recently acquired Teva facility in Goa, suggesting a positive outlook for future performance.